vs
NORTHERN TECHNOLOGIES INTERNATIONAL CORP（NTIC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NORTHERN TECHNOLOGIES INTERNATIONAL CORP的1.3倍（$30.3M vs $23.3M），NORTHERN TECHNOLOGIES INTERNATIONAL CORP净利率更高（1.0% vs -221.3%，领先222.4%），REGENXBIO Inc.同比增速更快（43.0% vs 9.2%），NORTHERN TECHNOLOGIES INTERNATIONAL CORP自由现金流更多（$-479.7K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 5.8%）
该企业为一家美国航天科技公司，专注于地理空间情报、地球观测、在轨卫星服务业务，同时提供卫星产品及相关配套服务。其由数字地球公司与MDA控股公司合并而成，于2017年10月5日正式完成合并组建。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NTIC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.3M
营收增速更快
RGNX
高出33.8%
9.2%
净利率更高
NTIC
高出222.4%
-221.3%
自由现金流更多
NTIC
多$52.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
5.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.3M | $30.3M |
| 净利润 | $237.8K | $-67.1M |
| 毛利率 | 36.0% | — |
| 营业利润率 | 4.0% | -190.0% |
| 净利率 | 1.0% | -221.3% |
| 营收同比 | 9.2% | 43.0% |
| 净利润同比 | -57.6% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NTICRGNX
| Q4 25 | $23.3M | $30.3M | ||
| Q3 25 | $22.3M | $29.7M | ||
| Q2 25 | $21.5M | $21.4M | ||
| Q1 25 | $19.1M | $89.0M | ||
| Q4 24 | $21.3M | $21.2M | ||
| Q3 24 | $23.3M | $24.2M | ||
| Q2 24 | $20.7M | $22.3M | ||
| Q1 24 | $20.8M | $15.6M |
净利润NTICRGNX
| Q4 25 | $237.8K | $-67.1M | ||
| Q3 25 | $-1.1M | $-61.9M | ||
| Q2 25 | $121.8K | $-70.9M | ||
| Q1 25 | $434.3K | $6.1M | ||
| Q4 24 | $561.1K | $-51.2M | ||
| Q3 24 | $1.8M | $-59.6M | ||
| Q2 24 | $976.6K | $-53.0M | ||
| Q1 24 | $1.7M | $-63.3M |
毛利率NTICRGNX
| Q4 25 | 36.0% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 38.4% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 38.3% | 70.2% | ||
| Q3 24 | 43.8% | 48.8% | ||
| Q2 24 | 38.2% | 52.5% | ||
| Q1 24 | 40.0% | 72.6% |
营业利润率NTICRGNX
| Q4 25 | 4.0% | -190.0% | ||
| Q3 25 | 4.2% | -176.3% | ||
| Q2 25 | 4.0% | -296.3% | ||
| Q1 25 | -1.7% | 13.6% | ||
| Q4 24 | 5.2% | -242.1% | ||
| Q3 24 | 11.8% | -256.6% | ||
| Q2 24 | 7.4% | -251.3% | ||
| Q1 24 | 10.6% | -408.8% |
净利率NTICRGNX
| Q4 25 | 1.0% | -221.3% | ||
| Q3 25 | -4.9% | -208.3% | ||
| Q2 25 | 0.6% | -331.8% | ||
| Q1 25 | 2.3% | 6.8% | ||
| Q4 24 | 2.6% | -241.3% | ||
| Q3 24 | 7.9% | -246.3% | ||
| Q2 24 | 4.7% | -237.7% | ||
| Q1 24 | 8.2% | -405.4% |
每股收益（稀释后）NTICRGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $-0.11 | $-1.20 | ||
| Q2 25 | $0.01 | $-1.38 | ||
| Q1 25 | $0.04 | $0.12 | ||
| Q4 24 | $0.06 | $-0.99 | ||
| Q3 24 | $0.19 | $-1.17 | ||
| Q2 24 | $0.10 | $-1.05 | ||
| Q1 24 | $0.17 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $72.4M | $102.7M |
| 总资产 | $104.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NTICRGNX
| Q4 25 | $6.4M | $230.1M | ||
| Q3 25 | $7.3M | $274.2M | ||
| Q2 25 | $6.8M | $323.3M | ||
| Q1 25 | $5.1M | $267.9M | ||
| Q4 24 | $5.6M | $234.7M | ||
| Q3 24 | $5.0M | $255.5M | ||
| Q2 24 | $5.8M | $290.4M | ||
| Q1 24 | $4.8M | $338.7M |
股东权益NTICRGNX
| Q4 25 | $72.4M | $102.7M | ||
| Q3 25 | $72.1M | $161.5M | ||
| Q2 25 | $72.4M | $213.7M | ||
| Q1 25 | $69.7M | $274.2M | ||
| Q4 24 | $70.2M | $259.7M | ||
| Q3 24 | $71.2M | $301.4M | ||
| Q2 24 | $68.9M | $348.3M | ||
| Q1 24 | $68.4M | $390.7M |
总资产NTICRGNX
| Q4 25 | $104.0M | $453.0M | ||
| Q3 25 | $102.7M | $525.2M | ||
| Q2 25 | $99.3M | $581.0M | ||
| Q1 25 | $93.7M | $490.9M | ||
| Q4 24 | $94.0M | $466.0M | ||
| Q3 24 | $94.7M | $519.1M | ||
| Q2 24 | $89.3M | $569.4M | ||
| Q1 24 | $87.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $341.9K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-479.7K | $-52.8M |
| 自由现金流率自由现金流/营收 | -2.1% | -174.0% |
| 资本支出强度资本支出/营收 | 3.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.44× | — |
| 过去12个月自由现金流最近4个季度 | $-1.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NTICRGNX
| Q4 25 | $341.9K | $-52.3M | ||
| Q3 25 | $-1.4M | $-56.0M | ||
| Q2 25 | $609.7K | $-49.3M | ||
| Q1 25 | $803.7K | $33.6M | ||
| Q4 24 | $2.4M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | $1.9M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流NTICRGNX
| Q4 25 | $-479.7K | $-52.8M | ||
| Q3 25 | $-1.4M | $-56.5M | ||
| Q2 25 | $-171.2K | $-49.7M | ||
| Q1 25 | $293.1K | $32.6M | ||
| Q4 24 | $1.2M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | $869.4K | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率NTICRGNX
| Q4 25 | -2.1% | -174.0% | ||
| Q3 25 | -6.3% | -189.9% | ||
| Q2 25 | -0.8% | -232.8% | ||
| Q1 25 | 1.5% | 36.6% | ||
| Q4 24 | 5.5% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | 4.2% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度NTICRGNX
| Q4 25 | 3.5% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 3.6% | 1.8% | ||
| Q1 25 | 2.7% | 1.2% | ||
| Q4 24 | 5.7% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 5.2% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率NTICRGNX
| Q4 25 | 1.44× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.01× | — | ||
| Q1 25 | 1.85× | 5.53× | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.99× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
